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Abstract  26 
Previous data obtained in piglets suggested that despite structural analogy with Bisphenol A 27 
(BPA), Bisphenol S (BPS) elimination may proceed more slowly, resulting in a much higher 28 
systemic exposure to unconjugated BPS than to BPA. Interspecies allometric scaling was 29 
applied to predict the toxicokinetic (TK) parameters of BPS, namely plasma clearance in 30 
humans from values obtained in animals, and thus contribute to assessment of the human 31 
internal exposure to BPS. 32 
Allometric scaling was performed using mean BPS plasma clearance values measured in rats 33 
after intravenous administration of 5 mg BPS /kg body weight (BW) and those previously 34 
obtained in piglets and sheep using identical IV BPS dosing and analytical procedures. 35 
The BPS plasma clearance, evaluated at 0.92 L/kg.h in rats, was proportional to species body 36 
weight, enabling the prediction of human BPS plasma clearance by extrapolating to a BW of 37 
70 kg. The estimated BPS plasma clearance in humans was thus 0.92 L/min (0.79 L/kg.h), i.e. 38 
about two times lower than the previously estimated BPA clearance (1.79 L/min). 39 
By increasing systemic exposure to the active moiety of an environmental estrogenic chemical, 40 
this less efficient clearance of BPS in humans, as compared with BPA, might worsen the 41 
harmful consequences of replacing BPA by BPS. 42 
 43 




Owing to great concern regarding the adverse effects of bisphenol A (BPA) on human health, 46 
restrictive measures have been applied that have led to its gradual replacement by structural 47 
analogues. Bisphenol S (BPS) is one of the main alternatives to BPA as a color developer in 48 
thermal papers and in the  manufacture of plastics and epoxy resins (Wu et al. 2018).  49 
The widespread and increasing use of BPS in consumer products is reflected by the high 50 
prevalence of BPS in urine from a cohort of US populations (Lehmler et al. 2018) and Asian 51 
countries (Liao et al. 2012). Despite insufficient data to assess the origin of such wide internal 52 
exposure, relevant pathways of human exposure to BPS could be the ingestion of BPS-53 
contaminated food or dust and direct contact of BPS-contaminated hands with the mouth 54 
resulting from hand-to-mouth activity. A review of the literature suggests that substituting BPA  55 
with BPS may not lower the risk of endocrine disruption since BPS has been shown to display 56 
estrogen-like effects at concentrations similar to BPA (Pelch et al. 2019). Both BPS and BPA 57 
are largely conjugated to glucuronides (Le Fol et al. 2015; Skledar et al. 2016; Zhou et al. 2014), 58 
which are considered inactive due to their lack of estrogenicity (Matthews et al. 2001; Skledar 59 
et al. 2016). So, by increasing the internal exposure to the active form of BPA, a lower in vivo 60 
BPS plasma glucuronidation rate, as shown in piglets (Gayrard et al. 2019), may still aggravate 61 
the harmful consequences of BPA substitution by BPS. Indeed in piglets, the 3.5 times lower 62 
plasma clearance (Cl) of BPS as compared with BPA, combined with its 100 times lower first-63 
pass glucuronidation following oral dosing, accounted for the 250 times higher systemic 64 
exposure to active unconjugated BPS (Gayrard et al. 2019). The relevance of this result for 65 
humans is supported by the higher serum concentrations of BPS, compared with BPA, that have 66 
been predicted for peroral exposure from a physiologically based toxicokinetic (TK) model 67 
(Karrer et al. 2018). However, the impossibility of directly measuring basic TK parameters in 68 
humans, such as plasma clearance, volume of distribution and mean residence time, limits our 69 
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understanding of the TK mechanisms underlying the different fates of bisphenol analogues, 70 
thus requiring assumptions when predicting BPS plasma kinetic profiles for external 71 
environmentally-relevant exposures. Clearance represents the most important TK parameter 72 
because it is the only parameter controlling the internal exposure following intravenous (IV) 73 
administration, as measured by the Area Under the plasma concentration vs time Curve (AUC). 74 
For an oral route of exposure, AUC is entirely controlled by both Cl and bioavailability (noted 75 
F). The steady-state volume of distribution (noted Vss) not only reflects the extent of 76 
distribution of a substance in the body but, in conjunction with Cl, also controls its persistence 77 
as measured by the Mean Residence Time (MRT). MRT is defined as the average time that a 78 
single molecule of the substance of interest remains in the body. Direct calculations of Cl, Vss 79 
and MRT require an IV injection that is impossible to carry out in man and an alternative 80 
approach consists of estimating these TK parameters by applying an indirect approach such as 81 
allometry. So-called simple allometric scaling consists of relating body size to a parameter of 82 
interest using a power equation (Chappell and Mordenti 1991). This has proved  to be a useful 83 
tool for predicting human clearance of BPA from animal data (Collet et al. 2015). In the present 84 
study, this approach was used to estimate the Cl, Vss and MRT of BPS in humans from plasma 85 
BPS kinetic profiles obtained in rats following IV BPS dosing and TK data previously obtained 86 
using identical IV BPS dosing and analytical procedures in piglets (Gayrard et al. 2019) and in 87 
pregnant and non-pregnant ewes (Grandin et al. 2017, 2018). 88 
 89 
Materials and methods 90 
Animal handling procedures and sample collection 91 
The experiment was declared to the regional Ethical Committee “Toxcomethique” (C2EA 92 
n°86) and to the French Ministry of Research. It was authorized by the French Ministry of 93 
Research under the number #5215_2016042815224143). The experiment was carried out with 94 
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15 female Wistar rats (Envigo, Gannat, France) weighing 266±26 g. They were fed ad libitum 95 
a commercial rat chow (2016 Teklad global 16% protein rodent diets, Envigo) and were housed 96 
individually in metabolism cages during the sampling periods. 97 
The rats, briefly anesthetized using volatile anesthesia (2 % isoflurane, AErrane®, Baxter SA, 98 
Maurepas, France, in 0.7 L/min of O2), were administered BPS into the lateral tail vein at a 99 
dose of 5 mg/kg. Serial blood samples (0.25 ml) were collected in propylene tubes before and 100 
at each of the designated time points post-administration: 10 min (n=8), 20 min (n=6), 30 min 101 
(n=8), 40 min (n=6), 60 min (n=8), 1.5h (n=6), 2h (n=8), 4h (n=5), 8h (n=8), 12h (n=6), 24h 102 
(n=8) and 36h (n=4), through a catheter surgically inserted in the left femoral vein under volatile 103 
anesthesia at least two days before BPS administration. After each blood sampling, 104 
physiological saline was administered at a volume equivalent to the withdrawn blood volume. 105 
The catheter was then filled with 200 µL of heparinized saline (50 IU/mL). Total urine was 106 
collected in propylene tubes at 3, 6, 9, 12, and 24 h after BPS administration in 9 rats. The 107 
volume of each urine sample and the sampling time were recorded. Blood and urine samples 108 
were immediately chilled on ice and centrifuged for 10 min at 3000 g at 4°C and the supernatant 109 
was stored in propylene tubes at -20°C until assayed. 110 
Test material and treatments 111 
All materials for the preparation of solutions, including the materials used for sampling, 112 
processing and analysis, were made of glass or polypropylene. BPS (purity >99%) was 113 
purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). BPS dosing solutions were 114 
extemporaneously prepared by dissolving BPS in ethanol-saline (1:4, vol:vol) at 5 mg/ml.  115 
BPS assay 116 
Analytes were quantified by Acquity ultra performance liquid chromatography coupled to a 117 
Xevo triple quadrupole mass spectrometer (Waters, Milford, MA, USA). BPS and BPSG in 118 
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plasma and urine samples were measured simultaneously, without resorting to a hydrolysis step, 119 
using the method described previously (Grandin et al. 2017). 120 
Toxicokinetic analyses 121 
The plasma mass concentrations were converted into molar concentrations before analysis. The 122 
cumulated molar quantities of excreted BPS (BPSG) in urine were calculated by multiplying 123 
the molar concentrations of BPS (BPSG) by the volume of urine at each sampling time.  124 
Plasma concentration-time profiles of BPS were analyzed using Phoenix (version 8.0 Pharsight 125 
Corporation) according to a non-compartmental approach (NCA) involving a sparse data 126 
option. Sparse data methodology consists of calculating TK parameters based on the mean 127 
profile of all the subjects in the dataset and is appropriate when no rich data series can be 128 
obtained, as in the present experiment. The AUC and the Area under the first moment curve 129 
from the time of dosing to the last measurable concentration, AUClast and AUMClast were 130 
calculated using the linear trapezoidal rule. The mean plasma concentration-time profile of 131 
BPSG was used to derive the maximum concentration (Cmax), the time to maximum 132 
concentration (Tmax), and the AUClast and AUMClast values. The Cl of BPS and apparent 133 
clearance of BPSG (Cl_F) were estimated after IV administration of BPS by dividing the dose 134 
by the AUClast calculated for each analyte as previously described. Vss and MRT were computed 135 
using the usual pharmacokinetic equations and the moment statistical approach (Gibaldi and 136 
Perrier 1983).  137 
Allometric approach 138 
Allometric scaling was based on the mean clearance and body weight data obtained in rats and 139 
those previously obtained using identical 5mg/kg IV BPS dosing and analytical procedures in 140 
female piglets (Gayrard et al. 2019), and in pregnant and  non-pregnant female sheep (Grandin 141 
et al. 2017, 2018). The data used for allometric scaling are given in Table 1. 142 
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 The mean clearance values (Cl) obtained in each animal species were plotted against the mean 143 
animal BW using the following standard power equations: 144 
𝐶𝑙 = 𝑎 × 𝐵𝑊
𝑏    Eq1 145 
where a and b are the allometric coefficient and the exponent of the allometric equation, 146 
respectively. 147 
The Cl and BW were transformed logarithmically and fitted to Equation 2 by linear regression 148 
analysis using SystatR (Version 11, Systat Software, Inc., San Jose California USA). 149 
𝑙𝑜𝑔𝐶𝑙 = 𝑙𝑜𝑔𝑎 + 𝑏 × 𝑙𝑜𝑔𝐵𝑊  Eq2 150 
where log a is the y-intercept, and b is the slope.  151 
Based on the animal data, the predicted value of Cl in humans was obtained by solving the 152 
allometric equation for a standard BW of 70 kg. Vss and MRT were scaled using the same 153 
approach as for Cl. Since the classical allometric relationship for Vss produced a very low and 154 
unexpected computed exponent (0.526) and predicted an unrealistically low Vss (0.267L/kg, 155 
see discussion), this approach was no longer considered to estimate Vss in man. The alternative 156 
approach proposed by Bachmann et al. (1996), based exclusively on rat Vss, was implemented 157 
to predict VSS in man using a power model with slope and intercept values of 0.91 and 0.705 158 
respectively. MRT was deduced from Cl and VSS estimates according to Equation 3. 159 
𝑀𝑅𝑇 = 𝑉𝑆𝑆/𝐶𝑙   Eq3 160 
 161 
Results 162 
BPS was not detected in any of the control samples obtained before the administrations, 163 
suggesting that little-to-no sample contamination had occurred during sample collection, 164 
processing and assay. The time course of plasma concentrations of BPS and BPSG in rats after 165 
IV administration is shown in Figure 1. Table 2 gives the values estimated by NCA for TK 166 
parameters of BPS and BPSG after IV BPS administration. The plasma concentration-time 167 
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profile of BPS was characterized by a phase of rapid decay of concentrations during the first 168 
four hours followed by a slow elimination phase. Plasma BPSG concentrations increased 169 
rapidly after IV administration of BPS, and the maximum BPSG concentration (Cmax) was 170 
attained within the first 10 minutes. After a rapid decline, an increase of BPSG plasma 171 
concentrations was observed about 4 h after BPS injection, after which the concentrations then 172 
decreased slowly from 12 h post dosing. The BPS Cl and BPSG Cl_F values were 0.92 L/kg.h 173 
and 0.18 L/kg.h, respectively. The respective values of BPS Vss and MRT were 3.64 L/kg and 174 
3.96 h. By 24h, the mean fraction of the BPS dose (± SD) recovered in urine was 37.5 ± 12.3% 175 
(n=9) mostly as BPSG (93.5 ± 7.1%), unconjugated BPS in urine representing 1.9 ± 2.1 % of 176 
the BPS dose. 177 
The allometric relationship between BW and Cl is shown in Figure 2. Data were fitted using 178 
equation 1 and the resulting allometric equation 4 was used to predict Cl according to BW.  179 
𝐶𝑙 = 0.0151 × BW0.968  Eq4  180 
with Cl in L/min, and BW in kg 181 
The 95 % confidence interval for the slope of the allometric relationship between BW and Cl 182 
(b value) was 0.8437 to 1.100 meaning that the slope was not significantly different from 1 with 183 
P > 0.05. On applying Equation 4, the estimated BPS Cl for a 70-kg human was 0.92 L/min 184 
(0.79 L/kg.h). Using the empirical model proposed by Bachmann et al. (1996), the estimated 185 
BPS Vss was  2.26 L/kg in man, based on  the rat Vss value of 3.6L/kg, and the deduced value 186 
of MRT was 2.86 h. 187 
 188 
Discussion 189 
Our estimates of BPS Cl, Vss and MRT in humans, based on scaling from animal data, provide 190 
some additional TK data for BPS. While the TK properties of BPA have been the subject of a 191 
large number of studies, to our knowledge this is the first study to describe the TK parameters 192 
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of BPS and BPSG after BPS IV dosing in rats, a species commonly used in toxicological 193 
studies.  194 
The BPS clearance in rats (0.92 L/kg.h) was shown to be equivalent to that previously estimated 195 
in larger species such as sheep (Grandin et al. 2017, 2018) and piglets (Gayrard et al. 2019) 196 
while the persistency of BPS as reflected by the MRT was 5 to 13 times higher (4 h) due to its 197 
5 to 21 times higher VSS (3.6 L/kg). The rebound in BPSG plasma concentrations, that peaked 198 
12 h post BPS IV dosing, may reflect the BPS enterohepatic recirculation  previously suggested 199 
by the rather high fecal excretion of BPS and its metabolites following IV administration in rats 200 
(32.5% of the dose, Waidyanatha et al. 2018). In the present experiment, the mean fraction of 201 
BPS dose recovered in urine over the 0-24 h post-dosing period was 37.5%, mostly in the form 202 
of BPSG, indicating that the renal clearance of unconjugated BPS was minimal. This result is 203 
consistent with those of other authors who reported that 42% of the radioactivity was eliminated 204 
in urine following injection of radiolabeled BPS in rats (Waidyanatha et al. 2018). This suggests 205 
that the clearance of BPS is driven by its biotransformation to more hydrophilic secondary 206 
metabolites (mainly BPSG) with subsequent elimination either in urine or bile. Enterohepatic 207 
recycling of BPA has been shown to occur in rats (Kurebayashi et al. 2003). An enterohepatic 208 
recirculation pathway has also been incorporated in the PBTK model of BPS for peroral 209 
exposure (Karrer et al. 2018) to improve the fitting of model predictions for BPS data 210 
biomonitoring (Oh et al. 2018) and to account for the longer persistence of BPS compared with 211 
BPA. The relevance of this modality of BPS elimination in humans is however questionable 212 
since BPSG has been shown to be cleared mostly by renal clearance in humans (Oh et al. 2018). 213 
The main result of our study is that BPS Cl can be estimated in man, with a good degree of 214 
confidence, by applying a simple allometric approach and selecting three species with BWs 215 
spanning a large range (from 0.2 to 77Kg BW). We were thus able to estimate Cl by 216 
interpolation and thereby reduce the uncertainties associated with extrapolation. In addition, the 217 
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coefficient of determination (R2) associated with the linear regression was very high (0.99) 218 
meaning that 99 % of the variability in BPS Cl between species was captured by the interspecies 219 
variation of BW. For the three species investigated, the allometric model predicted that the 220 
plasma Cl of BPS was directly related to BW and that the allometric exponent was not 221 
significantly different from 1. It has been argued that if the exponent of a simple allometric 222 
equation lies between 0.71 and 1, the product of Maximum Life-span potential (MLP) and 223 
clearance will predict Cl better than simple allometry (Mahmood and Balian 1996). We 224 
explored this so-called exponent rule to estimate the Cl in humans but did not find that such a 225 
correction was justified. The plasma Cl in man was thus estimated at a typical value of 226 
0.92 L/min for a BW of 70 kg (0.79 L/kg.h). Assuming that the plasma and blood BPS 227 
concentrations are equal, as observed in sheep (unpublished observations), it can be concluded 228 
that the blood BPS Cl in humans is equal to 18% of the cardiac output (about 5 L/min) and 60% 229 
of the hepatic blood flow rate (1.24 L/kg.h, i.e. 1.45L/min for a 70-kg BW, Davies and Morris 230 
1993). The mechanism of BPS Cl in man is unknown but assuming that all BPS is solely cleared 231 
by the liver (better case scenario for an oral exposure to an endocrine disruptor), the estimated 232 
hepatic extraction ratio (ERh) would therefore be 60%. The resulting fraction of BPS 233 
administered by oral route that escapes a hepatic first-pass effect can be as high as 40% (i.e. 1- 234 
ERh). This percentage will be even higher if a significant fraction of BPS is actually 235 
metabolized by some extra-hepatic mechanism such as renal clearance. This result is consistent 236 
with the bioavailability of BPS (57.4 %) that we directly measured in pigs (Gayrard et al. 2019). 237 
From our allometric estimate of BPS Cl in humans, it can therefore be tentatively concluded 238 
that if the liver is the only clearing organ of BPS in man (i.e. only an hepatic first-pass effect 239 
and no intestinal first-pass effect as we recently predicted in pigs, Gayrard et al. 2019), the oral 240 
bioavailability of BPS in man could be 50% or more. The relevance of a high BPS oral 241 
bioavailability in humans is strengthened  by the similar values obtained for human BPS plasma 242 
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clearance estimated by allometry (0.79 L/kg.h) and the apparent clearance values computed 243 
from observed time courses in volunteers reported by Oh et al. (2018), using the area under the 244 
curve of unconjugated BPS (61 L/h i.e. 0.88L/kg.h). The predicted BPS oral bioavailability in 245 
man is much higher than the systemic oral BPA bioavailability that has been evaluated at less  246 
than 1% in adult monkeys (Doerge et al. 2010). It should be understood that when the hepatic 247 
clearance approaches a value close to the hepatic blood flow (1.5 L/min in man), the resulting 248 
increased hepatic first-pass effect leads to a much higher than proportional decrease of the oral 249 
bioavailability. This  is likely the main explanation for  the much higher BPS oral bioavailability 250 
compared with BPA, as  shown in piglets (57.4% vs 0.50%, Gayrard et al. 2019). Indeed, the 251 
clearance of BPA in man (1.5 L/kg.h, Collet et al. 2015), mainly hepatic (Trdan Lušin et al. 252 
2012) is close to the human hepatic blood flow (1.24 L/kg.h, Davies and Morris 1993) thereby 253 
allowing a near total first-pass effect. On the other hand, BPS clearance (0.79L/kg.h), although 254 
only two times lower than that of BPA, is not enough to ensure a near total hepatic first-pass 255 
effect, and results in a much higher than proportional increase of BPS bioavailability compared 256 
with BPA. In humans, the lower estimated BPS clearance compared with that of BPA (0.79 vs 257 
1.5 L/kg.h, Collet et al. 2015) is consistent with the lower intrinsic hepatic clearance (0.4 vs 4.2 258 
L/kg/h) predicted from the BPS and BPA glucuronidation kinetic parameters in human liver 259 
microsomes (Karrer et al. 2018).  260 
The classical allometric relationship for Vss led to an unexpectedly low computed exponent of 261 
0.526 whereas for most drugs this exponent is around 1 (Mahmood 2010), and therefore 262 
predicted an unrealistically low Vss in man. This is why we implemented the approach 263 
proposed by Bachmann et al. (1996) who showed that the human volume of distribution for 100 264 
xenobiotics could  be well predicted solely from the rat Vss. Using this empirical model, the 265 
BPS Vss estimated from the rat VSS value (3.6 L/kg) was 2.26 L/kg in man. This prediction is 266 
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close to the reported human Vss/F that can be approximated at 5.15 L/kg by computing Vss/F 267 
from the human oral TK data published by Oh et al. (2018) and using equation 5. 268 
𝑉𝑆𝑆 = 𝐶𝑙 × 𝑀𝑅𝑇  Eq 5 269 
where Cl represents the apparent clearance of BPS (0.88 L/kg.h) and MRT is equal to 5.85 h  270 
An additional step for understanding the BPS disposition consists of considering the minimal 271 
model for Vss, as given by equation 6: 272 
𝑉𝑆𝑆 = 𝑉𝑃 +
𝑓𝑢
𝑓𝑢𝑇
× 𝑉𝑇   Eq 6 273 
where VP is the plasma volume, VT is the tissue volume, and fu and fuT are the fraction of 274 
unbound drug in plasma and tissue respectively. The unbound fraction of BPS in plasma has 275 
been shown to be slightly different in rats (0.15) and pregnant women (0.10, Gayrard, 276 
unpublished observation). Solving equation 6 with fu values for humans and rats and 277 
physiological values for human and rat tissues and plasma volumes (De Buck et al. 2007) 278 
predicts that fuT (a measure of BPS tissue affinity) would be very similar in rats (0.038) and 279 
man (0.053); this means that the difference in Vss between men and rats may simply reflect 280 
differences in the extent of BPS binding to plasma proteins. The lower VSS of BPS in humans 281 
compared with rats resulted in a lower MRT (2.86 h). 282 
Conclusion 283 
Based on our allometric approach, we conclude that BPS is less efficiently metabolized than 284 
BPA in humans, as reflected by its at least two-times lower plasma clearance. Since BPA 285 
substitution by BPS should lead to equivalent external exposures in terms of doses and routes, 286 
this lower BPS plasma clearance might lead to much higher oral serum concentrations of 287 
unconjugated BPS, as compared with BPA, due to the direct effect of a lower plasma clearance 288 
of BPS and indirectly by a much lower hepatic first-pass effect. Considering that BPA and BPS 289 
have comparable estrogen-like effects, our results suggest that oral BPS exposure might be 290 
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VSS (L/kg) MRT (h) 
Reference 
Female rats  15 0.27 ± 26.2 0.92 3.64 3.96 Present study 
Female piglets 
 
16 11.2 ± 1.42 0.95 ± 0.24 0.75 ± 0.38 0.75 ± 0.53 (Gayrard et al. 2019) 
Female sheep (not 
pregnant) 
 
4 59.6 ± 13.5 0.57 ± 0.13 0.17 ± 0.04 0.30 ± 0.04 (Grandin et al. 2017) 
Sheep (pregnant) 
 
6 77.4 ±12.3 0.99 0.38 0.38 (Grandin et al. 2018) 
VSS: Steady state volume of distribution 388 
MRT: Mean Residence Time 389 
 390 
Table 2: Toxicokinetic parameters of BPS and BPSG estimated by NCA analysis after BPS 391 
intravenous dosing. 392 
 393 
Toxicokinetic parameters BPS BPSG  
Cmax (µM) 27.3 17.0 
 
Tmax (h) NA 0.17 
 
AUClast (µM.h) 21.8 106.1 
 
Cl (L/kg.h) 0.92 NA 
 
Cl_F (L/kg.h) NA 0.18 
 
VSS (L/kg) 3.64 NA 
 
MRT (h) 3.96 14.2 
 
The toxicokinetic parameters of BPS and BPSG were estimated after IV administration of BPS 394 
at 20 µmoles/kg (5mg/kg).  395 
AUClast: Area under the plasma concentration-time curve from dosing time to the time of the 396 
last measurable plasma concentration 397 
BPS: Bisphenol S 398 
BPSG: Bisphenol S glucuronide 399 
Cl: Clearance 400 
Cl_F: Apparent clearance 401 
VSS: Steady state volume of distribution 402 
MRT: Mean Residence Time 403 
NA: not applicable  404 
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Figure captions 405 
 406 
Figure 1: Semi-logarithmic plots of the plasma concentrations (µM) of BPS and BPSG versus 407 
time (h) in rats (n=15) following IV administration of BPS at 5 mg/kg. 408 
 409 
Figure 2: Allometric scaling plot for BPS plasma clearance (Cl). Data were obtained in rats 410 
(open circle), piglets (closed circle), non-pregnant sheep (open triangle), and pregnant sheep 411 
(closed triangle). The continuous line represents linear regression analysis of all the data points. 412 
The allometric equation is provided and the open square indicates where a 70-kg BW adult 413 
human falls with the corresponding equation. 414 
